You are here

Healthcare Economics


A new reimbursement model for cardiac care delivery could launch as early as July 1, 2017—giving cardiologists less than a year to prepare to practice in an environment with more risks and different opportunities. Get engaged now, say the experts. 

In 2015, the median compensation for cardiologists working in hospital integrated practices increased to $577,756, and the median compensation for cardiologists working in private groups increased to $486,777, according to a survey from MedAxiom.

The American College of Cardiology (ACC) submitted comments to the Centers for Medicare & Medicaid Services (CMS) on Sept. 6 regarding the Hospital Outpatient Prospective Payment System (OPPS) for 2017.

Recently, it’s become more popular to offer smokers cash or financial incentives to quit the addictive habit. So far, the results have been mixed, although a study of low-income smokers in Switzerland showed that offering money could be effective in certain populations.

A simulation model of U.S. adults found that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were not cost-effective in patients with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD).



Recent Headlines

Abbott: Revenue increased in 3rd quarter for coronary devices, endovascular products

For the third quarter of 2016, Abbott’s sales increased 2.9 percent to $5.3 billion compared with the same time period last year. The company also posted a $0.24 loss in diluted earnings per share, which it said was primarily due to a $0.66 per share adjustment related to its investment in Mylan.

St. Jude Medical criticizes release of videos alleging its cardiac devices are vulnerable to hacking

Shortly after a research firm posted videos Oct. 19 that allegedly showed cybersecurity vulnerabilities with St. Jude Medical’s cardiac devices, the company issued a statement criticizing the release of the videos.

Abbott, St. Jude Medical agree to sell vascular closure, electrophysiology assets

Abbott and St. Jude Medical announced Oct. 18 that the companies agreed to sell a portion of their vascular closure and electrophysiology business for $1.12 billion to Terumo Corporation.

Cryoballoon catheter ablation saves money, leads to fewer rehospitalizations

Patients with atrial fibrillation who received cryoballoon catheter ablation had lower healthcare costs and fewer rehospitalizations and repeat ablations compared with those who received radiofrequency ablation, according to a health economic analysis.

St. Jude Medical warns of premature battery depletion in some cardiac devices

St. Jude Medical issued an advisory Oct. 11 warning of premature battery depletion associated with lithium deposits in a small number of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy ICDs.

Theranos closes laboratories, lays off 340 employees

Theranos founder and CEO Elizabeth Holmes announced on Oct. 5 that the blood testing company would close its laboratories and wellness centers in Arizona, California and Pennsylvania.

AstraZeneca cuts sales goals for blood thinner after disappointing results

AstraZeneca announced on Oct. 4 that patients with symptomatic peripheral artery disease who took ticagrelor (Brilinta) did not have better outcomes than those who received clopidogrel, a rival blood thinner.

AMGA submits comments to CMS on cardiac care bundled payments

Accountable care organizations (ACOs) should play a major role for the cardiac care bundled payments model that the Centers for Medicare & Medicaid Services (CMS) proposed in July, according to the American Group Medical Association (AMGA).

AHA, 7 other groups file lawsuit against the FDA for not enforcing tobacco rule

Eight medical organizations, antitobacco groups and three pediatricians filed a federal lawsuit on Oct. 4 against the U.S. Food and Drug Administration (FDA). They want the agency to enforce The Tobacco Control Act and issue a final rule requiring graphic health warnings on cigarette packs and advertising.

Aralez agrees to acquire rights to popular blood thinner from AstraZeneca

For the second time in less than a month, Aralez Pharmaceuticals has struck a deal with a major pharmaceuticals company for a cardiovascular medication.